Clinical Trial Update: A Study of Bevacizumab to Prevent Malignant Ascites [Phase 2]

View source ↗

Summary

This document reports the withdrawal of a Phase 2 trial evaluating bevacizumab to prevent malignant ascites.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Malignant Ascites | Phase 2 | Status: WITHDRAWN